In summary, in this study we show that PD-L1 is upregulated in tumor and immune cells in a subset of Western GBC in late tumorigenesis and provide evidence for TIGIT/CD155 axis as a new immune checkpoint for complement therapy in GBC. This evidence concerns the gene PVR and neoplasm.